

Comments from PM
Short Term Studies

- 1) Spell out BM names fully 1st time used in Synopsis and in body of CSR.
 - a) Use abbreviation thereafter.
- 2) Synopsis will including: *only* key Results, Discussion, and Conclusions from the body of the report.
 - a) Very succinct, minimal narrative, bulleted lists (or tables??) whenever possible.
- 3) The word treatment must be in quotations (e.g., "Treatment").
 - a) It is preferred to use this only when another term, such as Group, is inadequate.
- 4) Capitalize Acclimation, Baseline Day, and Day 1, etc.
 - a) Use EITHER "per day" or "per 24h" CONSISTENTLY.
- 5) Present comparisons between Groups in standardized order; always group of interest 1st (e.g., PREP).
 - a) Do NOT use terms such as "original data values" unless unavoidable.
 - b) Do not use "data Type 1 (or 2, 3, 4)".
 - c) Give exact units and name for the biomarker of interest.
 - d) Tables for BM adjusted for cpd should read: *BM adj for number of cigs smoked per day (BM mass/cig) or Mean BM adj for number of cigs smoked per day versus study day by treatment (% change from Baseline)*.
 - i) NOT *Mean BM versus study day by treatment (% change from Baseline adj for number of cigs smoked per day)*.
- 6) Adjust ONLY 24h urine biomarkers of exposure for cpd.
 - a) CLARIFICATION: units are ng/mL per cig
 - b) DELETE 8-epi-PGF_{2a}, 11-DHT, urine albumin adjusted for number of cigs smoked per day (correlation w/ cpd scientifically valid ONLY for BOE at this point).
 - c) EVERY BIOMARKER TABLE/FIGURE TITLE/AXIS SHOULD STATE THE BM UNITS USED (e.g., mass/day, mass/cig).
 - i) *ALL* should have a numerator *AND* a denominator (e.g., usually mass/day or mass/cig).
 - d) Correct units for NE are mg/day and mg/cig. Need *urine* before *albumin* (always, including TOC Table titles).

- 7) For regression analyses, *only* Day -1 and Day 8 are important.
 - a) Present R² and slope of statistically significant relationships.
 - b) Use R² and not R2. If there are statis signif correlations:
- 8) Questionnaire analysis:
 - a) *Fagerstrom Test for Nicotine Dependence* is correct nomenclature.
- 9) *ELIMINATE THE TERMS “DOSE” (e.g., Table 14.3.1.1), PREDOSE, POSTDOSE, DRUG.*
- 10) The Conclusions in the Synopsis should include all the collated Conclusions from the body of the report.
- 11) Use past **tense** consistently throughout. Active **voice** is preferred to passive.
- 12) Post-text order of BMs (for Tables, Figures, Appendices) should match that in-text, and should be BOE, then BED, then BOPH as follow:
 - a) BOE: NE, Cotinine, NNAL, 3-HPMA, S-PMA, 1-OHP, mutagenicity
 - b) BED: COHb AUC₍₇₋₂₃₎ (*this is the actual BM in this study, not COHb itself*)
 - c) BOPH: Triglycerides, HDL-C, LDL-C, fibrinogen, hs-CRP, total bilirubin, 8-*epi*-PGF_{2a}, 11-dehydro-TxB₂, urine albumin.
- 13) Be certain that all trademark symbols are superscripts.
- 14) Always, italicize *epi*, *trans*, *cis*, *S*-, *N*-, *O*..
- 15) Never capitalize *epi*-, *trans*-, *cis*-, hs (as in high-sensitivity). This means that, when one of these begins a bullet or sentence, in which the first word should be capitalized, instead capitalize the NEXT word (e.g., 8-*epi*-Prostaglandin..., 11-Dehydro-thromboxane...).
- 16) In the List of Abbreviations, be consistent in capitalizing the first word in the abbreviations.
- 17) Add a dictionary of terms that defines: nicotine equivalents; biomarker of exposure; biomarker of potential harm; biomarker of effective dose; potential-reduced exposure product, vital signs, hematology; controlled; smoking topography.
- 18) Center all in-text tables.
- 19) Be consistent with the spelling of Fagerstrom or Fagerström.
- 20) Present “mean±sd” rather than mean/sd.
- 21) Use abbreviations for chemicals following their first appearance in the text.
- 22) Replace “restricted” with “controlled” and “unrestricted” with “uncontrolled”.

- 23) Indicate multiplication by an “x”, e.g., ppm x hr.
- 24) Replace “nicotine and its five metabolites” with “nicotine equivalents”.
- 25) Use “subject” (not “patient”).
- 26) Use “adult smokers” (not “smokers”).
- 27) Use “in-house study” or “controlled, in-house study” (not “confinement study”).
- 28) Use singular “Week” when used as an adjective for the noun “visit” (e.g., Week 2, 4, 6, and 12 visits), but plural “Weeks” when used as a noun (e.g., at Weeks 2, 4, 6, and 12).
- 29) Spell out state names (e.g., Virginia instead of VA).
- 30) Be consistent in EITHER spelling out OR using numerals for numbers < 12 (e.g., 7 instead of seven). I prefer we use numerals.
- 31) Use military time instead of civilian time (e.g., 01:30 instead of 1:30 a.m., 23:00 instead of 11:00 p.m.).
- 32) Italicize *e.g.*, and *i.e.*.
- 33) Use high-sensitivity CRP or hs-CRP (not HS-CRP).
- 34) Nicotine, cotinine, *trans*-3'-hydroxycotinine, and NNAL listed by name alone without “free” or “total” descriptors implies the free biomarker (excludes any conjugated portion). *Since most of these compounds exist in the free form, the deconjugation step is not routinely done unless specified.*
- 35) Use “total 1-OHP” (not 1-OHP).
- 36) Use “particulate phase”, “gas phase” or “gas/vapor phase” (no hyphens in U.S. English, only British English).
- 37) Use tobacco smoke “constituents” (not “components”).
- 38) Use cigarette “delivery” (not “yield”).
- 39) In the CSR (Volume 1), give full descriptive stats (N, mean, SD, median, range, 95% CI) for EACH **biomarker** in the post-text tables.

- 40) Send *one* sturdily-bound **hard copy** of the ENTIRE draft CSR (EVERYTHING that's on the CD-ROM) with the electronic copy.
- 41) Include in Volume 1 of the CSR: a comprehensive **Table of Contents** that includes all TOC for Volume 1 AND for all subsequent individual Volumes of the CSR. On both the electronic copy and hard copy (spine and cover), prominently number each volume as <*Volume x of xx*> where xx represents the final volume of the CSR (e.g., Volume 10 of 37).
- 42) **Lists of Abbreviations, Definitions, and Calculations:** Include any terms with a specific meaning for THAT study that may be misinterpreted by the reader if the intended meaning is not defined (e.g., controlled smoking; unrestricted smoking; residual effect; nicotine equivalents). Repeat any study-specific **calculations** in the data analysis section (e.g., for nicotine equivalents, residual effect adjustments).